October 31, 2019 / 11:42 AM / a month ago

BRIEF-Dicerna & Roche To Develop DCR-HBVS For Treatment Of Chronic Hepatitis B Virus Infection

Oct 31 (Reuters) - Dicerna Pharmaceuticals Inc:

* DICERNA ENTERS AGREEMENT WITH ROCHE TO DEVELOP AND COMMERCIALIZE DCR-HBVS FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION

* DICERNA PHARMACEUTICALS - ROCHE TO GAIN WORLDWIDE LICENSE TO CO’S NOVEL RNAI THERAPY CURRENTLY IN PHASE 1

* DICERNA PHARMACEUTICALS - TO RECEIVE $200 MILLION UP FRONT PLUS UP TO $1.47 BILLION IN POTENTIAL MILESTONE PAYMENTS RELATED TO DCR-HBVS

* DICERNA PHARMACEUTICALS - CO, ROCHE TO COLLABORATE ON RESEARCH AND DEVELOPMENT OF MORE THERAPIES TARGETING MULTIPLE HUMAN, VIRAL GENES IMPLICATED IN CHRONIC HBV INFECTION

* DICERNA PHARMACEUTICALS - TO RETAIN OPTION TO CO-FUND PIVOTAL DEVELOPMENT OF DCR-HBVS WORLDWIDE & CO-PROMOTE IN U.S. WITH ENHANCED ROYALTIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below